The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated results of a phase 1/2 study of AU-007, a monoclonal antibody (mAb) that binds to IL-2 and inhibits CD25 binding, in patients with advanced solid tumors.
 
Drew W. Rasco
Research Funding - 23andMe (Inst); Abbvie (Inst); Adcentrx Therapeutics (Inst); Arcus Biosciences (Inst); Ascentage Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Aulos Bioscience (Inst); Boehringer Ingelheim (Inst); Bolt Biotherapeutics (Inst); Bristol-Myers Squibb/Celgene (Inst); Compugen (Inst); Constellation Pharmaceuticals (Inst); Cullinan Oncology (Inst); Eikon Therapeutics (Inst); Flare Therapeutics (Inst); GlaxoSmithKline (Inst); Johnson & Johnson/Janssen (Inst); Kronos (Inst); Merck (Inst); Molecular Templates (Inst); PureTech (Inst); Seven and Eight Biopharmaceuticals (Inst); Surface Oncology (Inst); Takeda (Inst); TD2 (Inst)
 
Meredith McKean
Consulting or Advisory Role - Castle Biosciences (Inst); IQVIA (Inst); Merck (Inst); Moderna Therapeutics (Inst); Pfizer (Inst)
Research Funding - AADi (Inst); Alpine Immune Sciences (Inst); Arcus Biosciences (Inst); Arvinas (Inst); Ascentage Pharma Group (Inst); ASCO (Inst); Astellas Pharma (Inst); Aulos Bioscience (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); BioMed Valley Discoveries (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); C4 Therapeutics (Inst); Dragonfly Therapeutics (Inst); EMD Serono (Inst); Epizyme (Inst); Erasca, Inc (Inst); Exelixis (Inst); Foghorn Therapeutics (Inst); G1 Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); IDEAYA Biosciences (Inst); Ikena Oncology (Inst); Immvira (Inst); Infinity Pharmaceuticals (Inst); Jacobio (Inst); Kechow Pharma (Inst); Kezar Life Sciences (Inst); Kinnate Biopharma (Inst); MedImmune (Inst); Mereo BioPharma (Inst); Metabomed (Inst); Moderna Therapeutics (Inst); NBE Therapeutics (Inst); Nektar (Inst); Novartis (Inst); NucMito Pharmaceuticals (Inst); OncoC4 (Inst); Oncorus (Inst); OnKure (Inst); PACT Pharma (Inst); Pfizer (Inst); Plexxikon (Inst); Poseida (Inst); Prelude Therapeutics (Inst); Pyramid Biosciences (Inst); Regeneron (Inst); Sapience Therapeutics (Inst); Scholar Rock (Inst); Seagen (Inst); Synthorx (Inst); Tempest Therapeutics (Inst); TeneoBio (Inst); Tizona Therapeutics, Inc. (Inst); Tmunity Therapeutics, Inc. (Inst); Top Alliance BioScience (Inst); Xilio Therapeutics (Inst)
 
Andrew Mark Haydon
Honoraria - Merck; Novartis; Novartis
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis
Speakers' Bureau - Bristol-Myers Squibb; Merck; Novartis
Expert Testimony - BMS
 
Andrew James Weickhardt
Honoraria - Eisai; Merck Sharp & Dohme
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer; Telix Pharmaceuticals
Speakers' Bureau - Astellas Pharma
Research Funding - Merck
Travel, Accommodations, Expenses - Astellas Pharma; Ipsen; Merck Sharp & Dohme
 
Sophia Frentzas
Leadership - CANCER TRIALS AUSTRALIA
Consulting or Advisory Role - GOG Foundation; MSD Oncology
Research Funding - Akeso Biopharma (Inst); Ambrx (Inst); Amgen (Inst); AstraZeneca (Inst); Aulos Bioscience (Inst); BeiGene (Inst); Cullinan Oncology (Inst); Daiichi Sankyo/UCB Japan (Inst); Edison Oncology (Inst); Haihe Pharmaceutical (Inst); MSD Oncology (Inst); Takeda (Inst); Vivace Therapeutics (Inst)
 
Elizabeth Stephanie Ahern
Honoraria - MSD Oncology
Research Funding - Amgen (Inst)
Patents, Royalties, Other Intellectual Property - U.S. Provisional Application No. 62/775803
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb
 
John D. Powderly
Employment - BioCytics; Carolina BioOncology Institute
Leadership - BioCytics; Carolina BioOncology Institute
Stock and Other Ownership Interests - BioCytics; Carolina BioOncology Institute
Consulting or Advisory Role - Aavocyte; Abbvie; AstraZeneca/MedImmune; Boxer Capital; Genentech/Roche; Phanes Therapeutics; TERUMO; TopAlliance BioSciences Inc
Research Funding - Abbvie; Adagene (Inst); Alkermes; Allarity Therapeutics (Inst); Apros Therapeutics; Aptevo Therapeutics (Inst); Arcus Biosciences; Ascendis Pharma (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune; Atreca (Inst); Aulos Bioscience (Inst); BioBank Online (Inst); BioNTech SE (Inst); BJ Bioscience (Inst); Bristol-Myers Squibb; Calico; Cellgene Corp. (Inst); CEM Corporation (Inst); Conjupro Biotherapeutics (Inst); Corbus Pharmaceuticals (Inst); Corvus Pharmaceuticals; CUE BioPharma (Inst); Cullinan Oncology (Inst); Curis; EMD Serono; Engineered BioPharmaceuticals (Inst); Fate Therapeutics (Inst); FLX Bio; Function Oncology (Inst); Genentech/Roche; GI Innovation (Inst); Glenmark Specialty SA (Inst); Harbour BioMed (Inst); I-Mab (Inst); IconOVir Bio (Inst); IgM Biosciences (Inst); Immune-Onc Therapeutics (Inst); Incyte; Jounce Therapeutics; Lilly/ImClone; Macrogenics; MBrace Therapeutics Inc. (Inst); Medikine (Inst); Merck (Inst); Modena TX (Inst); Molecular Templates (Inst); MT Group (Inst); Multitude Therapeutics Inc (Inst); NextCure (Inst); Nuvation Bio (Inst); PBD Biologics LTD (Inst); PEEL Therapeutics (Inst); Phanes Therapeutics (Inst); Pieris Pharmaceuticals (Inst); Pioma Chemicals (Inst); Precision for Medicine (Inst); Qurgen (Inst); Repertoire Immune Medicines (Inst); Replimune (Inst); Revolution Medicines Inc. (Inst); RiboScience (Inst); Sairopa (Inst); Seagen; Sequenom (Inst); Simcere (Inst); SK Life Sciences (Inst); STEMCELL Technologies (Inst); Tempest Therapeutics; Therapeutic BrainPower LLC (Inst); Top Alliance BioScience; Trethera (Inst); Xilio Therapeutics (Inst); Xilis (Inst); Zenshine (Inst)
Patents, Royalties, Other Intellectual Property - BioCytics is developing intellectual property for cellular immunotherapy
 
Timothy Wyant
Employment - Abpro; Aulos Bioscience; Biolojic; Curis
Leadership - Aulos Bioscience; Biolojic
Stock and Other Ownership Interests - Aulos Bioscience; Biolojic
Patents, Royalties, Other Intellectual Property - WO/219 087292 A1, US-20200289477-A1 Conjoint therapies for Immunomodulation. 2019 Sasikumar; Pottayil Govindan N. et al.; WO2022003690A3 Anti-tumor necrosis factor receptor (tnfr2) antibodies and uses thereof
Travel, Accommodations, Expenses - Biolojic
 
Jenny Tang
Employment - Aulos Bioscience
Stock and Other Ownership Interests - Aulos Bioscience
 
Lori Richards
Employment - Aulos Bioscience
Stock and Other Ownership Interests - Aulos Bioscience
 
Aron Knickerbocker
Employment - Aulos Bioscience
Leadership - Aulos Bioscience; KAHR Medical; Phenomic AI
Stock and Other Ownership Interests - Aulos Bioscience; KAHR Medical; Phenomic AI; RayzeBio
 
Inbar Amit
Employment - Biolojic Design Israel
Stock and Other Ownership Interests - Biolojic Design Israel
Patents, Royalties, Other Intellectual Property - Biolojic Design Israel
 
Yanay Ofran
Employment - Biolojic Design Israel
Leadership - Biolojic Design Israel
Stock and Other Ownership Interests - Biolojic Design Israel
Consulting or Advisory Role - Biolojic Design Israel
Patents, Royalties, Other Intellectual Property - Biolojic Design Israel
 
James Robert Vasselli
Employment - Aulos Bioscience
Leadership - Aulos Bioscience
Stock and Other Ownership Interests - Aulos Bioscience